TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16536815

Group type: EXPERIMENTAL
Intervention: LED system (40 J cm(‐2); 80 mW cm(‐2))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incoherent lamp (100 J cm(‐2); 160 mW cm(‐2))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LED system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incoherent lamp
Number of subjects: 40
Study: 12680079

Group type: EXPERIMENTAL
Intervention: All-ceramic restorations
Number of subjects: 0
Study: 11706694

Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid screws
Number of subjects: 91

Group type: COMPARATOR
Intervention: Titanium screws
Number of subjects: 91
Study: 9770556

Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Response to soy milk
Number of subjects: 65
Study: 7921429

Group type: EXPERIMENTAL
Intervention: Salmeterol treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3166046

Group type: EXPERIMENTAL
Intervention: Red rubber urethral catheter (RRUC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acrylic stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: No stabilization
Number of subjects: 0
Study: 31039001

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly crosslinked polyethylene insert (study group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional polyethylene insert (control group)
Number of subjects: 200
Study: 28329223

Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Number of subjects: 65

Group type: COMPARATOR
Intervention: In-person follow-up care
Number of subjects: 65
Study: 25499302

Group type: EXPERIMENTAL
Intervention: PCI with sirolimus-eluting stents (SES)
Number of subjects: 130

Group type: COMPARATOR
Intervention: MIDCAB surgery
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 130
Study: 23446962

Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD), 1.2 g·kg BW(-1)·d(-1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal-protein diet (NPD), 0.8 g·kg BW(-1)·d(-1)
Number of subjects: 72
Study: 22080658

Group type: EXPERIMENTAL
Intervention: Glove use
Number of subjects: 7578

Group type: COMPARATOR
Intervention: No glove use
Number of subjects: 7578
Study: 19061937

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-penetrating placebo needles
Number of subjects: 10
Study: 16519594

Group type: EXPERIMENTAL
Intervention: Complex messages promoting fruit and vegetable consumption
Number of subjects: 517

Group type: COMPARATOR
Intervention: Simple messages promoting fruit and vegetable consumption
Number of subjects: 517
Study: 15257930

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after induction therapy with idarubicin, cytarabine, and etoposide.
Number of subjects: 258

Group type: COMPARATOR
Intervention: Candidates not undergoing ASCT.
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Induction therapy with idarubicin, cytarabine, and etoposide.
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for patients with unfavorable cytogenetics, age over 70 years, or leukocytosis.
Number of subjects: 258
Study: 11464255

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 64
Study: 9283510

Group type: EXPERIMENTAL
Intervention: Alprazolam-exposure
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo-exposure
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Alprazolam-relaxation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo-relaxation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Patients' classifications in alprazolam group
Number of subjects: 129

Group type: COMPARATOR
Intervention: Patients' classifications in placebo group
Number of subjects: 129
Study: 29671767

Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (3.3, 5.0, or 7.5 g of protein)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Free Amino Acid Mixture (2.5 g)
Number of subjects: 11
Study: 27644034

Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG vaccine (5 μg, 20 μg, or 80 μg) administered intramuscularly at 0, 1, and 6 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG vaccine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 52
Study: 25425377

Group type: EXPERIMENTAL
Intervention: Sonographic classification of chorionicity
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Sonographic examinations before 14 weeks' gestation
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Each week increase in gestational age
Number of subjects: 545
Study: 22781642

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy followed by surgery (arm A)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Surgery alone (arm B)
Number of subjects: 123
Study: 19458364

Group type: EXPERIMENTAL
Intervention: Dipyridamole plus aspirin (200 mg dipyridamole and 25 mg aspirin, twice daily)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 649
Study: 16951298

Group type: EXPERIMENTAL
Intervention: Exercise group (N = 11), prescribed a conditioning program of aerobic and lower-body resistance training 3 days per week.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (N = 12)
Number of subjects: 41
Study: 15532134

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch (20 micrograms of ethinylestradiol and 150 micrograms of norelgestromin)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 3300
Study: 17690815

Group type: EXPERIMENTAL
Intervention: Tubular bandaging material
Number of subjects: 15

Group type: COMPARATOR
Intervention: Short‐stretch medical compression bandages
Number of subjects: 15

Group type: COMPARATOR
Intervention: Long‐stretch medical compression bandages
Number of subjects: 15
Study: 9597955

Group type: EXPERIMENTAL
Intervention: Primary surgery (laryngectomy) and radiotherapy (RT)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Induction chemotherapy (CT) and radiotherapy (RT)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Total laryngectomy patients
Number of subjects: 332
Study: 7941816

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the evening (10.00 p.m.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the morning (6.00 a.m.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the evening (10.00 p.m.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the morning (6.00 a.m.)
Number of subjects: 100
Study: 3258862

Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 56
Study: 29895954

Group type: EXPERIMENTAL
Intervention: Epoetin-α 450 IU/kg/week
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 28825515

Group type: EXPERIMENTAL
Intervention: Egg-based, trivalent, inactivated split influenza vaccine
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 1390
Study: 25764482

Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5%
Number of subjects: 323

Group type: COMPARATOR
Intervention: Topical voriconazole, 1%
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5% (subgroup analysis for Fusarium species)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Topical voriconazole, 1% (subgroup analysis for Fusarium species)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5% (for Aspergillus or other non-Fusarium species)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Topical voriconazole, 1% (for Aspergillus or other non-Fusarium species)
Number of subjects: 323
Study: 22990223

Group type: EXPERIMENTAL
Intervention: Higher doses of nicotine replacement therapy (NRT)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Lower doses of nicotine replacement therapy (NRT)
Number of subjects: 633
Study: 20529203

Group type: EXPERIMENTAL
Intervention: Self-management workshop (6-week intervention, weekly 2-hour sessions based on cognitive-behavioral principles)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Self-management workshop
Number of subjects: 132

Group type: COMPARATOR
Intervention: Information-only intervention
Number of subjects: 132
Study: 18563636

Group type: EXPERIMENTAL
Intervention: Higher OEF regions (OEF > 50)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lower OEF regions (OEF < 30)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High OEF regions (OEF > 70)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: One subject in high OEF region (>70)
Number of subjects: 8
Study: 16415448

Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica montana
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15223002

Group type: EXPERIMENTAL
Intervention: L-DOPA (400 mg) + CarbiDOPA (100 mg)
Number of subjects: 8
Study: 11509480

Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sedentary activity for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9007745

Group type: EXPERIMENTAL
Intervention: Severe carotid stenosis
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Mild or moderate carotid disease
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: CT scan showing infarction
Number of subjects: 384
Study: 8329922

Group type: EXPERIMENTAL
Intervention: Active opportunistic testing
Number of subjects: 5529

Group type: EXPERIMENTAL
Intervention: Passive opportunistic testing
Number of subjects: 5529

Group type: EXPERIMENTAL
Intervention: Testing by appointment after letter invitation
Number of subjects: 5529

Group type: EXPERIMENTAL
Intervention: Testing by appointment after letter and leaflet invitation
Number of subjects: 5529

Group type: EXPERIMENTAL
Intervention: Testing by appointment after late letter invitation
Number of subjects: 5529

Group type: EXPERIMENTAL
Intervention: Active opportunistic testing by appointment
Number of subjects: 5529

Group type: EXPERIMENTAL
Intervention: Positive test result
Number of subjects: 5529

Group type: EXPERIMENTAL
Intervention: Negative test result
Number of subjects: 5529
Study: 2434802

Group type: EXPERIMENTAL
Intervention: Perindopril (4, 8, and 16 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31846808

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 I.U.)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: BPD patients
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 113
Study: 30963205

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg IV
Number of subjects: 214

Group type: COMPARATOR
Intervention: Saline IV
Number of subjects: 214
Study: 28430326

Group type: EXPERIMENTAL
Intervention: Accurus system (group 1)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Constellation system (group 2)
Number of subjects: 61
Study: 25646057

Group type: EXPERIMENTAL
Intervention: Stromal hydration
Number of subjects: 60

Group type: COMPARATOR
Intervention: No stromal hydration
Number of subjects: 60
Study: 24329696

Group type: EXPERIMENTAL
Intervention: Estrogen only (n=168)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Combined estrogen-progesterone (n=117)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Postmenopausal women without HT (n=360)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Premenopausal women (n=140)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Estrogen substitution therapy (follow-up study)
Number of subjects: 885
Study: 22058298

Group type: EXPERIMENTAL
Intervention: Cemented prosthesis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cementless prosthesis
Number of subjects: 50
Study: 19339404

Group type: EXPERIMENTAL
Intervention: Walnut diet (42.5 g walnuts/10.1 mJ)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fish diet (113 g salmon, twice/wk)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet (no nuts or fish)
Number of subjects: 25
Study: 16905208

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (45Gy in 25 fractions + 5-FU)
Number of subjects: 30
Study: 15577135

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 11730735

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐pertechnetate vaginally (0.2 mL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐pertechnetate vaginally (0.2 mL) with sealed cervical canal
Number of subjects: 6

Group type: COMPARATOR
Intervention: (99m)Tc‐pertechnetate intravenously
Number of subjects: 6
Study: 9200272

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8254957

Group type: EXPERIMENTAL
Intervention: Breast conserving treatment, quadrantectomy with or without immediate reconstruction, axillary dissection, internal mammary biopsy, and breast irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 2888736

Group type: EXPERIMENTAL
Intervention: Ro 23-0364 (0.25 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ro 23-0364 (0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ro 23-0364 (1.0 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30357556

Group type: EXPERIMENTAL
Intervention: Opioid switching
Number of subjects: 498
Study: 28901662

Group type: EXPERIMENTAL
Intervention: Mild hypoxia (end-tidal PO2 74 ± 2 mmHg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (end-tidal PO2 50 ± 3 mmHg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GTN-induced dilatation during mild hypoxia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GTN-induced dilatation during moderate hypoxia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normoxic time control (30 min)
Number of subjects: 30
Study: 25219699

Group type: EXPERIMENTAL
Intervention: GreenLight XPS
Number of subjects: 291

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 291
Study: 24463577

Group type: EXPERIMENTAL
Intervention: ePREP (computer-based preventive intervention)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Active placebo control group
Number of subjects: 52
Study: 22565005

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 774

Group type: COMPARATOR
Intervention: Placebo in combination with chemotherapy
Number of subjects: 774
Study: 19724045

Group type: EXPERIMENTAL
Intervention: Adequately registered trials (147 trials)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Trials lacking registration (89 trials)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Trials registered after completion (45 trials)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Trials with unclear primary outcomes (39 trials)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Trials with discrepancies (46 trials)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Statistically significant results in discrepancies (23 trials)
Number of subjects: 323
Study: 17541059

Group type: EXPERIMENTAL
Intervention: Percent body fat
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa subtype
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serum cortisol levels
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serum leptin levels
Number of subjects: 32
Study: 15383114

Group type: EXPERIMENTAL
Intervention: Total hysterectomy
Number of subjects: 279

Group type: COMPARATOR
Intervention: Subtotal hysterectomy
Number of subjects: 279
Study: 12128107

Group type: COMPARATOR
Intervention: 70 Gy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study: 9850489

Group type: EXPERIMENTAL
Intervention: Glipizide gastrointestinal therapeutic system (GITS)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study: 7924707

Group type: EXPERIMENTAL
Intervention: Coloanal anastomosis
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ileoanal anastomosis
Number of subjects: 29
Study: 2679967

Group type: EXPERIMENTAL
Intervention: Dietary restrictions during Haemoccult retesting
Number of subjects: 18925

Group type: COMPARATOR
Intervention: Normal diet during initial Haemoccult testing
Number of subjects: 18925

Group type: EXPERIMENTAL
Intervention: Retesting after 3 months with dietary restrictions
Number of subjects: 18925
Study: 1245939

Group type: EXPERIMENTAL
Intervention: Inactivated monovalent influenza B vaccine (0.25 ml containing 250 chick cell agglutinating units)
Number of subjects: 45
Study: 30663593

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vincristine 1·4 mg/m2 [maximum 2·0 mg]
Number of subjects: 0
Study: 27866713

Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis (n=42)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group with laparoscopy alone (n=31)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 27423289

Group type: EXPERIMENTAL
Intervention: Ipsilateral TAP block with bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 40
Study: 23112275

Group type: EXPERIMENTAL
Intervention: Biodegradable synthetic polyurethane foam (BSPF)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Silicone intranasal septal splint (INS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 68
Study: 21646588

Group type: EXPERIMENTAL
Intervention: Immunization navigator intervention (immunization tracking, reminder/recall, home visits)
Number of subjects: 7546

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 7546
Study: 19736359

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride therapy for 6 months
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Marked improvement in depression (Clinical Global Impression-Improvement subscale score of 1)
Number of subjects: 361
Study: 17034955

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 8 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: BclI polymorphism carriers
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: BclI carriers in high ACTH tertile
Number of subjects: 98
Study: 12759221

Group type: EXPERIMENTAL
Intervention: TPNGLN (glutamine-supplemented TPN, 0.4 g.kg‐1.day‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: TPN (conventional parenteral nutrition)
Number of subjects: 19

Group type: COMPARATOR
Intervention: TPNGLN
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TPNGLN + GH/IGF‐I (GH 0.2 IU.kg‐1.day‐1 and IGF‐I 160 microg.kg‐1.day‐1)
Number of subjects: 19
Study: 11020677

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dimenhydrinate 50 mg
Number of subjects: 74
Study: 9545747

Group type: EXPERIMENTAL
Intervention: Laparoscopic colon resection
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Open colon resection
Number of subjects: 1500
Study: 8290465

Group type: EXPERIMENTAL
Intervention: Povidone-iodine alcoholic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Povidone-iodine aqueous solution
Number of subjects: 0
Study: 3984975

Group type: EXPERIMENTAL
Intervention: Naproxen sodium loading dose of 550 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Naproxen sodium therapy
Number of subjects: 45
Study: 31564004

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 103

Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 103
Study: 30348154

Group type: COMPARATOR
Intervention: Fluorescent dusts treated inserts
Number of subjects: 0
Study: 27595104

Group type: EXPERIMENTAL
Intervention: Probiotic mixture F_1
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Probiotic mixture F_2
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo F_3
Number of subjects: 150
Study: 24874781

Group type: EXPERIMENTAL
Intervention: Clinician-targeted intervention using the 5As approach
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Group 2 clinicians
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Group 1 clinicians
Number of subjects: 319
Study: 21210268

Group type: EXPERIMENTAL
Intervention: Menthol drops applied topically with standard therapy (topical clotrimazole)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo with standard therapy (topical clotrimazole)
Number of subjects: 84
Study: 16142002

Group type: EXPERIMENTAL
Intervention: Topical gel containing gaïazulene and dimeticone
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 233
Study: 12483625

Group type: EXPERIMENTAL
Intervention: Ad libitum feeding
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional feeding protocol
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 9536918

Group type: EXPERIMENTAL
Intervention: Mild indirect cooling (cool water immersion at 16 degrees C for 2 min, 6 times)
Number of subjects: 90
Study: 7897032

Group type: EXPERIMENTAL
Intervention: Socially competent children and their mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive children and their mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxious children and their mothers
Number of subjects: 0
Study: 2694314

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Ivermectin 150 mcg/kg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 mcg/kg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198